



Ifw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **TERADA, Hiroshi, et al.**

Group Art Unit: 1618

Serial No.: 10/525,964

Examiner: **HARTLEY, Michael G.**

Filed: **October 13, 2005**

P.T.O. Confirmation No.: 3134

For: **REMEDY**

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

March 16, 2007

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

TERADA, Hiroshi, et al.

Serial No.: 10/525,964

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS,

HANSON & BROOKS, LLP

James E. Armstrong, IV

Attorney for Applicant

Reg. No. 42,266

JAM/aoa

Atty. Docket No. 050106

Suite 1000

1725 K Street, N.W.

Washington, D.C. 20006

(202) 659-2930



23850

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449 and references (5)



<b>INFORMATION DISCLOSURE CITATION PTO-1449</b>	Atty. Docket No. <b>050106</b>	Serial No. <b>10/525,964</b>
	Applicant(s): <b>TERADA, Hiroshi, et al.</b>	
	Filing Date: <b>October 13, 2005</b>	Group Art Unit: <b>1618</b>

#### U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
____	AA					
____	AB					

#### FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
____			
____	AC		
____	AD		

#### OTHER DOCUMENTS

____	AE	S. Suarez et al.; "Airways delivery of rifampicin microparticles for the treatment of tuberculosis," Journal of Antimicrobial Chemotherapy; Vol. 48, No. 3; 2001; pp. 431-434 and cover page.
____	AF	H. Inagawa et al.; "Anti-tumor Effect of Lipopolysaccharide by Intradermal Administration as a Novel Drug Delivery System;" Anticancer Research; Vol. 17; 1997; pp. 2153-2158.
____	AG	H. Inagawa et al.; "Antitumor Mechanism of Intradermal Administration of Lipopolysaccharide;" Anticancer Research; Vol. 17; 1997; pp. 1961-1964 and cover page.
____	AH	G-I. Soma; "Dynamic Aspects of Cytokine Network to Induce Antitumor Effects by Intradermal Administration of Low Molecular Weight Lipopolysaccharide Derived from <i>Pantoea Agglomerans</i> ;" Advances in Pharmaceutical Sciences; Vol. 16; 2000; Japan; pp. 7-22 and publisher info. page. / partial translation is attached (3 sheets).
____	AI	H. Kasugai; "Experimental study of antitumor effect of lipopolysaccharide extracted from <i>Pantoea agglomerans</i> ;" Teikyo Medical Journal; Vol. 21; No. 5; 1998; Japan; pp. 389-402 and publisher info. page. / partial translation is attached (2 sheets).
Examiner /Paul Dickinson/		
Date Considered 02/27/2008		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./